Stock 4151 KYOWA KIRIN CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Kyowa Kirin Co. Ltd. Stock

Equities

4151

JP3256000005

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-10-04 am EDT 		5-day change 1st Jan Change
2,626.00 JPY -0.04% Intraday chart for Kyowa Kirin Co. Ltd. +0.52% +10.80%
Oct. 03 Kyowa Kirin Buys Back 696,400 Shares for 2.26 Billion Yen in September MT
Oct. 02 Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. CI

Valuation: Kyowa Kirin Co. Ltd.

Capitalization 1,381B 9.43B P/E ratio 2024 *
20.2x
P/E ratio 2025 * 18.4x
Enterprise value 1,047B 7.15B EV / Sales 2024 *
2.14x
EV / Sales 2025 * 2.01x
Free-Float
44.06%
Yield 2024 *
2.21%
Yield 2025 * 2.33%
More valuation ratios * Estimated data

Chart: Kyowa Kirin Co. Ltd.

Dynamic Chart

Latest news: Kyowa Kirin Co. Ltd.

Kyowa Kirin Buys Back 696,400 Shares for 2.26 Billion Yen in September Oct. 02 MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. Oct. 02 CI
Kyowa Kirin Buys Back Shares for Over 3 Billion Yen in August Sep. 03 MT
Kyowa Kirin to End Distribution of Fareston in the United States Aug. 23 CI
Jefferies Adjusts Kyowa Kirin's Price Target to 3,700 Yen From 3000 Yen, Keeps at Buy Aug. 05 MT
DKSH Business Unit Healthcare and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific Aug. 04 CI
Kyowa Kirin's Profit Up 75% in Fiscal H1 Aug. 02 MT
Japanese Shares Nosedive Amid Wall Street Losses and Rising Yen Aug. 02 MT
Kyowa Kirin Shakes Up APAC Strategy, Sells China Operations to Hong Kong Firm Aug. 02 MT
Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024 Aug. 01 CI
Kyowa Kirin Buys Back Shares Jul. 03 MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024. Jul. 02 CI
Kyowa Kirin Repurchases 3.3 Million Shares in May Jun. 05 MT
More news

Analysts' recommendations: Kyowa Kirin Co. Ltd.

Jefferies Adjusts Kyowa Kirin's Price Target to 3,700 Yen From 3000 Yen, Keeps at Buy Aug. 05 MT
Jefferies Adjusts Kyowa Kirin’s Price Target to 3,000 Yen From 3,600 Yen, Keeps at Buy 23-10-09 MT
Jefferies Adjusts Kyowa Kirin's Price Target to 3,600 Yen From 3,900 Yen, Keeps at Buy 23-03-30 MT
More recommendations

Press Releases: Kyowa Kirin Co. Ltd.

Kyowa Kirin : Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis Sep. 25 PU
Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting Sep. 20 AQ
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024 Aug. 29 AQ
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States Aug. 26 AQ
Kyowa Kirin : Transcript of Results Briefing Fiscal 2024 Second Quarter (0B) Aug. 06 PU
More press releases

News in other languages: Kyowa Kirin Co. Ltd.

Rally di quattro sedute del Nikkei si interrompe su prese profitto Sep. 25
DKSH erhält Auftrag von Kyowa Kirin aus Japan Aug. 02
EEUU aprueba la primera terapia de genes para niños con una rara enfermedad hereditaria Mar. 18
MÄRKTE ASIEN/Tokio sehr fest auf 34-Jahreshoch - Softbank mit Kurssprung Feb. 08
Kyowa Kirin schließt erfolgreich die Übernahme von Orchard Therapeutics ab, einem Weltmarktführer für Gentherapie bei seltenen Krankheiten Jan. 24
More news

Quotes and Performance

1 day-0.04%
1 week+2.08%
Current month+3.92%
1 month-19.45%
3 months-10.60%
6 months+0.38%
Current year+10.80%
More quotes

Course Extremes

1 week
2 481.00
Extreme 2481
2 645.00
1 month
2 481.00
Extreme 2481
3 313.00
Current year
2 266.50
Extreme 2266.5
3 350.00
1 year
2 266.50
Extreme 2266.5
3 350.00
3 years
2 266.50
Extreme 2266.5
3 875.00
5 years
1 849.00
Extreme 1849
4 240.00
10 years
1 094.00
Extreme 1094
4 240.00
More quotes

Managers and Directors: Kyowa Kirin Co. Ltd.

Director TitleAgeSince
Motohiko Kawaguchi DFI
 Director of Finance/CFO - 86-03-31
Masashi Miyamoto PSD
 President 65 85-03-31
Takuo Hirose CTO
 Chief Tech/Sci/R&D Officer 53 18-09-30
Manager TitleAgeSince
Toshifumi Mikayama BRD
 Director/Board Member 67 08-09-30
Masashi Miyamoto PSD
 President 65 85-03-31
Yutaka Osawa CMP
 Compliance Officer 65 84-03-31
More insiders

ETFs: Kyowa Kirin Co. Ltd.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
2.22% 14 M€ +14.70%
GLOBAL X MSCI GOVERNANCE-QUALITY JAPAN ETF - JPY ETF Global X MSCI Governance-Quality Japan ETF - JPY
0.44% 4 M€ +13.64% -
More ETFs: Kyowa Kirin Co. Ltd.

Specialty & Advanced Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
-0.04%+2.08%+2.98%-33.18%9.41B
MERCK KGAA Stock Merck KGaA
-1.07%-3.52%+0.10%-15.40%75.02B
YUHAN CORPORATION Stock Yuhan Corporation
-2.31%-7.93%+92.96%+163.92%7.82B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-0.87%-4.45%+19.61%+2.08%6.05B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
+14.13%+24.24%-19.75%-50.89%2.74B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+18.45%+30.14%+0.32%+64.47%2.66B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+9.99%+14.21%+26.94%+35.89%2.5B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
+16.48%+27.02%-52.54%-68.77%1.8B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
-0.19%+4.32%+18.49%+17.93%1.77B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-.--%-.--% - - 1.64B
Average +5.45%+13.52%+9.90%+12.89% 11.14B
Weighted average by Cap. +0.32%+1.18%+7.59%-1.30%
See all sector performances

Financials

2024 *2025 *
Net sales 489B 3.34B 499B 3.41B
Net income 68.84B 470M 74.09B 506M
Net Debt -334B -2.28B -380B -2.6B
More financial data * Estimated data

Company Profile

Logo Kyowa Kirin Co. Ltd.
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (7.4%). At the end of 2021, the group had 3 production sites located in Japan (2) and China. Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Employees
5,974
Sector
Pharmaceuticals
Calendar
2024-10-30 - Q3 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
24-10-04 2,626.00 ¥ -0.04% 1,821,500
24-10-03 2,627.00 ¥ +1.53% 2,117,800
24-10-02 2,587.50 ¥ +1.83% 2,889,700
24-10-01 2,541.00 ¥ +0.55% 2,081,000
24-09-30 2,527.00 ¥ -1.77% 3,714,000

Delayed Quote Japan Exchange, October 04, 2024 at 02:00 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,627.00JPY
Average target price
3,362.50JPY
Spread / Average Target
+28.00%
Consensus
Profit revisions
Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4151 Stock